Skip to main content
SpringerLink
Log in

Overview of COX-2 in inflammation: from the biology to the clinic

  • Chapter
Inducible Enzymes in the Inflammatory Response

Part of the book series: Progress in Inflammation Research ((PIR))

Abstract

Cyclooxygenase (COX) is part of a bifunctional enzyme, prostaglandin H synthase (PGHS), which catalyzes the first step in the conversion of membrane phospholipids (principally, arachidonic acid) into prostanoids (prostaglandins and thromboxanes). Prostanoids contribute to diverse physiological and pathological processes including inflammation. Non-steroidal anti-inflammatory drugs (NSAIDs), the prototype of which is aspirin, owe their therapeutic effects to blockade of prostaglandin synthesis through COX blockade [1]. NSAIDs are a heterogenous group of compounds, often chemically unrelated, which nevertheless share therapeutic effects (i.e. antiinflammatory, analgesic and antipyretic) and side effects (i.e. gastrointestinal erosions, decreased renal function, inhibition of platelet aggregation). Until recently, it had been widely accepted that a common mechanism (COX inhibition) is responsible for both the therapeutic and the side-effects of NSAIDs. However, this theory has been refined since the discovery of a second, inducible COX isozyme, COX-2 [2, 3]. It has been proposed that COX-2 inhibition is relevant for the anti-inflammatory effects of NSAIDs, whereas inhibition of constitutive COX-1 is responsible for the gastric and renal side effects, as well as for the antithrombotic activity of these agents [4].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Vane JR (1971) Inhibition of prostaglandin synthesis as a mechanism of action of aspirin-like drugs. Nature 231: 232–235

    CAS  Google Scholar 

  2. Fu JY, Masferrer JL, Seibert K, Raz A, Needleman P (1990) The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 265: 16737–16740

    PubMed  CAS  Google Scholar 

  3. Fletcher BS, Kujubu DA, Perrin DM, Herschmann HR (1992) Structure of the mitogeninducible TIS 10 gene and demonstration that the TIS10-encoded protein is a functional prostaglandin G/H synthase. J Biol Chem 267: 4338–4344

    PubMed  CAS  Google Scholar 

  4. Vane JR (1994) Towards a better aspirin. Nature 367: 215–216

    Article  PubMed  CAS  Google Scholar 

  5. Raz A, Wyche A, Siegel N, Needleman P (1988) Regulation of fibroblast cyclooxygenase synthesis by interleukin-1. J Biol Chem 263: 3022–3025

    PubMed  CAS  Google Scholar 

  6. Raz A, Wyche A, Needleman P (1989) Temporal and pharmacological division of fibroblast cyclooxygenase expression into transcriptional and translational phases. Froc Natl Acad Sci USA 86: 1657–1661

    Article  CAS  Google Scholar 

  7. Masferrer JL, Zweifel BS, Seibert K, Needleman P (1990) Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. J Clin Invest 86: 1375–1379

    Article  PubMed  CAS  Google Scholar 

  8. Masferrer JL, Seibert K, Zweifel BS, Needleman P (1992) Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme. Proc Natl Acad Sci USA 89: 3917–3921

    Article  PubMed  CAS  Google Scholar 

  9. Wong WYL, DeWitt DL, Smith WL, Richards JS (1989) Rapid induction of prostaglandin endoperoxide synthase induced by luteinizing hormone and cAMP is blocked by inhibitors of transcription and translation. Mol Endocrinol 3: 1714–1723

    Article  PubMed  CAS  Google Scholar 

  10. Wong WYL, Richards JS (1991) Evidence for two antigenically distinct molecular weight variants of prostaglandin H synthase in the rat ovary. Mol Endocrinol 5: 1861–1868

    Article  Google Scholar 

  11. Sirois J, Richard JS (1992) Purification and characterization of a novel, distinct isoform of prostaglandin endoperoxide synthase induced by human chorionic gonadotrophin in granulosa cells of rat preovulatory follicles. J Biol Chem 267: 11586–11592

    PubMed  CAS  Google Scholar 

  12. Rosen GD, Birkenmeier TM, Raz A, Holtzman MJ (1989) Identification of cyclooxyge-nase-related gene and its potential role in prostaglandin formation. Biochem Biophys Res Commun 164: 1358–1365

    Article  PubMed  CAS  Google Scholar 

  13. Xie W, Chipman JG, Robertson DL, Erikson RL, Simmons DL (1991) Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 88: 1692–1696

    Google Scholar 

  14. Kujubu DA, Fletcher BS, Varnum BC, Lim R, Herschman HR (1991) TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J. Biol Chem 266: 12866–12872

    PubMed  CAS  Google Scholar 

  15. O’Banion MK, Sadowski HB, Winn V, Young DA (1991) A serum-and glucocorticoidregulated 4-kilobase mRNA encodes a cyclooxygenase-related protein. J. Biol Chem 266: 2361–2367

    Google Scholar 

  16. Kujubu DA, Herrschman HR (1992) Dexamethasone inhibits mitogen induction of the TISIO prostaglandin synthase/cyclooxygenase gene. J. Biol Chem 267: 7991–7994

    PubMed  CAS  Google Scholar 

  17. DeWitt DL, Smith WL (1988) Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence. Proc Natl Acad Sci USA 85: 1412–1416

    Article  PubMed  CAS  Google Scholar 

  18. Merlie JP, Pagan D, Mudd J, Needleman P (1988) Isolation and characterization of the complementary DNA for sheep seminal vesicle prostaglandin endoperoxide synthase (cyclooxygenase). J. Biol Chem 263: 3550–3553

    PubMed  CAS  Google Scholar 

  19. Yokoyama C, Takai T, Tanabe T (1988) Primary structure of sheep prostaglandin endoperoxide synthase deduced from cDNA sequence. FEBS Lett 11: 371–386

    Google Scholar 

  20. DeWitt DL, El-Harth A, Kraemer SA, Andrews MJ, Yao EF, Armstrong RL, Smith WL (1990) The aspirin and heme binding sites of ovine and murine prostaglandin endoperoxide synthases. J. Biol Chem 265: 5192–5198

    PubMed  CAS  Google Scholar 

  21. Feng L, Sun W, Xia Y, Tang WW, Chanmugam P, Soyoola E, Wilson CB, Hwang D (1993) Cloning two isoforms of rat cyclooxygenase: differential regulation of their expression. Arch Biochem Biophys 307: 361–388

    Article  PubMed  CAS  Google Scholar 

  22. Yokoyama C, Tanabe T (1989) Cloning of human gene encoding prostaglandin endoperoxide synthase and primary structure of the enzyme. Biochem Biophys Res Commun 165: 888–894

    Article  PubMed  CAS  Google Scholar 

  23. Funk CD, Funk LB, Kennedy ME, Pong S, Fitzgerald GA (1991) Human platelet/ery-throleukemia cell prostaglandin G/H synthase: cDNA cloning, expression and gene chromosomal assignment. FASEB J 5: 2304–2312

    PubMed  CAS  Google Scholar 

  24. Takahashi Y, Ueda N, Yoshimoto T, Yamamoto S, Yokoyama C, Miyata A, Tanabe T, Fuse I, Hattori A, Shibata A (1992) Immunoaffinity purification and cDNA cloning of human platelet prostaglandin endoperoxide synthase (cyclooxygenase). Biochem Bio-phys Res Commun 197: 494–500

    Google Scholar 

  25. Xie W, Merril JR, Bradshaw WS, Simmons DL (1993) Structural determination and promoter analysis of the chicken mitogen-inducible prostaglandin G/H synthase gene and genetic mapping of the murine homologue. Arch Biochem Biophys 300: 247–252

    Article  PubMed  CAS  Google Scholar 

  26. Fletcher BS, Kujubu DA, Perrin DM, Herschman HR (1992) Structure of the mitogen-inducible TIS10 gene and demonstration that the TISlO-encoded protein is a functional prostaglandin G/H synthase. J. Biol Chem 267: 4338–4344

    PubMed  CAS  Google Scholar 

  27. Kennedy BP, Chan CC, Gulp SA, Cromlish WA (1993) Cloning and expression of rat prostaglandin endoperoxide synthase (cyclooxygenase)-2 cDNA. Biochem Biophys Res Commun 197: 494–500

    Article  PubMed  CAS  Google Scholar 

  28. Sirois J, Levy LO, Simmons DL, Richards JS (1993) Characterization and hormonal regulation of the promoter of the rat endoperoxide synthase 2 gene in granulosa cells. J Biol Chem 268: 7384–7385

    Google Scholar 

  29. Yamagata K, Andreasson KI, Kaufmann WE, Barnes CA, Worley PF (1993) Expression of a mitogen-inducible cyclooxygenase in brain neurones: regulation by synaptic activity and glucocorticoids. Neurons 11: 371–386

    Article  CAS  Google Scholar 

  30. Hla T, Neilson K (1992) Human cyclooxygenase-2 cDNA. Froc Natl Acad Sci USA 89: 7384–7388

    Article  CAS  Google Scholar 

  31. Jones DA, Carlton DP, Mclntyre TM, Zimmerman GA, Prescott SM (1993) Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J. Biol Chem 268: 9049–9054

    PubMed  CAS  Google Scholar 

  32. Appleby SB, Ristimäki A, Neilson K, Narko K, Hla T (1994) Structure of the human cyclo-oxygenase-2 gene. Biochem J 302: 723–727

    PubMed  CAS  Google Scholar 

  33. Picot D, Loll PJ, Garavito RM (1994) The X-ray crystal structure of the membrane pro tein prostaglandin H2 synthase-1. Nature 367: 243–249

    Article  PubMed  CAS  Google Scholar 

  34. Loll PJ, Garavito RM (1994) The isoforms of cyclooxygenase: structure and function. Curr Opin Invest Drugs 3: 1171–1180

    CAS  Google Scholar 

  35. Luong C, Miller A, Barnett J, Chov J, Ramesha C, Brovner MF (1996) Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2. Nature Struct Biol 3: 927–933

    Article  PubMed  CAS  Google Scholar 

  36. Browner MF (1996) X-ray crystal structure of human cyclooxygenase-2. In: N Bazan J Botting J Vane (eds): New targets in inflammation: inhibitors of COX-2 and adhesion molecules. Kluwer Academic Publishers Dordrecht 71–7

    Google Scholar 

  37. Akarasereenont P, Mitchell JA, Appleton I, Thiemermann C, Vane JR (1994) Involvement of tyrosine kinase in the induction of cyclo-oxygenase and nitric oxide synthase by endotoxin in cultured cells. Br J Pharmacol 113: 1522–1528

    Article  PubMed  CAS  Google Scholar 

  38. Arias-Negrete S, Keller K, Chadee K (1995) Proinflammatory cytokines regulate cyclooxygenase-2 mRNA expression in human macrophages. Biochem Biophys Res Commun 208: 582–589

    Article  PubMed  CAS  Google Scholar 

  39. Swierskosz TA, Mitchell JA, Warner TD, Botting RM, Vane JR (1995) Coinduction of nitric oxide synthase and cyclo-oxygenase: interactions between nitric oxide and prostanoids. Brit J Pharmacol 114: 1335–1342

    Article  Google Scholar 

  40. Barrios-Rodiles M, Keller K, Belley A, Chadee K (1996) Nonsteroidal anti-inflammatory drugs inhibit cyclooxygenase-2 enzyme activity but not mRNA expression in human macrophages. Biochem Biophys Res Commun 225: 896–900

    Article  PubMed  CAS  Google Scholar 

  41. Nüsing R, Ullrich V (1992) Regulation of cyclooxygenase and thromboxane synthase in human monocytes. Eur J Biochem 206: 131–136

    Article  PubMed  Google Scholar 

  42. Glaser KB, Lock YW (1995) Regulation of prostaglandin H synthase 2 expression in human monocytes by the marine natural product manoalide and scalaradial. Biochem Pharmacol 50: 913–922

    Article  PubMed  CAS  Google Scholar 

  43. Patrignani P, Santini G, Panara MR, SciuUi MG, Greco A, Rotondo MT, Giamberardi-no M, Maclouf J, Ciabattoni G, Patrono C (1996) Induction of prostaglandin endoperoxide synthase-2 in human monocytes associated with cyclo-oxygenase-dependent F2-isoprostane formation. Brit J Pharmacol 118: 1285–1293

    Article  CAS  Google Scholar 

  44. Lee SH, Soyoola E, Chanmungam P, Hart S, Sun W, Zhong H, Liou S, Simmons D, Hwang D (1992) Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide. J Biol Chem 267: 25934–25938

    PubMed  CAS  Google Scholar 

  45. O’SuUivan MG, Chilton FH, Huggins EM, McCall CE (1992) Lipopolysaccharide priming of alveolar macrophages for enhanced synthesis of prostanoids involves induction of a novel prostaglandin H synthase. J Biol Chem 267: 14547–14550

    Google Scholar 

  46. Thivierge M, Rola-Pleszczynski M (1995) Up-regulation of inducible cyclooxygenase gene expression by platelet-activating factor in activated rat alveolar macrophages. J Immunol 154: 6593–6599

    PubMed  CAS  Google Scholar 

  47. Tordjman C, Coge F, Andre N, Rique H, Spedding M, Bonnet J (1995) Characterisation of cyclooxygenase 1 and 2 expression in mouse resident peritoneal macrophages in vitro; interactions of non steroidal anti-inflammatory drugs with COX2. Biochim Biophys Acta 1256: 249–256

    Article  PubMed  Google Scholar 

  48. Hinson RM, Williams JA, Shacter E (1996) Elevated interleukin 6 is induced by prostaglandin E2 in a murine model of inflammation: possible role of cyclooxygenase-2. Proc Natl Acad Sci USA 93: 4885–4890

    Article  PubMed  CAS  Google Scholar 

  49. Misko TP, Trotter JL, Cross AH (1995) Mediation of inflammation by encephalogenic cells: interferon induction of nitric oxide synthase and cyclooxygenase 2. J Neuroimmunol 61: 195–204

    Article  PubMed  CAS  Google Scholar 

  50. Quinn MR, Park E, Schuller-Levis G (1996) Taurine chloramine inhibits prostaglandin E2 production in activated raw 264.7 cells by post-transcriptional effects on inducible cyclooxygenase expression. Immunol Lett 50: 185–188

    Article  PubMed  CAS  Google Scholar 

  51. Martin M, Neumann D, Hoff T, Resch K, DeWitt DL, Goppelt-Struebe M (1994) Inter-leukin-1-induced cyclooxygenase 2 expression is suppressed by cyclosporin A in rat mesangial cells. Kidney Internat 45: 150–158

    Article  CAS  Google Scholar 

  52. Rzymkiewicz D, Leungang K, Baird N, Morrison AR (1994) Regulation of prostaglandin endoperoxide synthase gene expression in rat mesangial cells by inter-leukin-lß. Am J Physiol 266: F39–F45

    PubMed  CAS  Google Scholar 

  53. Fiebich B, Biber K, Lieb K, van Calker D, Berger M, Bauer J, Gebicke-Haerter PJ (1996) Cyclooxygenase-2 expression in rat microglia is induced by adenosine A2a-receptors. Glia 18: 152–160

    Article  PubMed  CAS  Google Scholar 

  54. O’Banion MK, Miller JC, Chang JW, Kaplan MD, Coleman PD (1996) Interleukin-lß induces prostaglandin G/H synthase-2 (cyclooxygenase-2) in primary murine astrocyte cultures. J Neurochem 66: 2532–2540

    Article  PubMed  Google Scholar 

  55. Feng L, Xia Y, Garcia GE, Hwang D, Wilson CB (1995) Involvement of reactive oxygen intermediates in cyclooxygenase-2 expression induced by interleukin-1, tumor necrosis factor-a, and lipopolysaccharide. J Clin Invest 95: 1669–1675

    Article  PubMed  CAS  Google Scholar 

  56. Tetsuka T, Baier LD, Morrison AR (1996) Antioxidants inhibit interleukin-1-induced cyclooxygenase and nitric-oxide synthase expression in rat mesangial cells. J Biol Chem 271: 11689–11693

    Article  PubMed  CAS  Google Scholar 

  57. Corbett JA, Kwon G, Marino M, Rodi CP, Sullivan PM, Turk J, McDaniel ML (1996) Tyrosine kinase inhibitors prevent cytokine-induced expression of iNOS and COX-2 by human islets. Am J Physiol 270: C1581–C1587

    PubMed  CAS  Google Scholar 

  58. Chanmugam P, Feng L, Liou S, Jang BC, Boudreau M, Yu G, Lee JH, Kvon HJ, Beppu T, Yoshida M et al. (1995) Radicicol, a protein tyrosine kinase inhibitor, suppresses the expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide and in experimental glomerulonephritis.J Biol Chem 270: 5418–5426

    Article  PubMed  CAS  Google Scholar 

  59. Hwang D, Fischer NH, Jang BC, Tak H, Kim JK, Lee W (1996) Inhibition of the expression of inducible cyclooxygenase and proinflammatory cytokines by sesquiterpene lactones in macrophages correlates with the inhibition of MAP kinases. Biochem Biophys Res Commun 116: 810–818

    Article  Google Scholar 

  60. Tetsuka T, Srivastava SK, Morrison AR (1996) Tyrosine kinase inhibitors, genistein and herbimycin A, do not block interleukin-1ß-induced activation of NF-ΚB in rat mesangial cells. Biochem Biophys Res Commun 218: 808–812

    Article  PubMed  CAS  Google Scholar 

  61. Dolecki GJ, Rogers M, Lefkowith JB (1995) Discordance between macrophage arachidonate metabolic phenotype and the expression of cytosolic phospholipase A2 and cyclooxygenase. Prostaglandins 49: 397–414

    Article  PubMed  CAS  Google Scholar 

  62. Wilborn J, DeWitt DL, Peters-Golden M (1995) Expression and role of cyclooxygenase isoforms in alveolar and peritoneal macrophages. Am J Physiol 268: L294–L301

    PubMed  CAS  Google Scholar 

  63. Rothenberg RJ (1987) Modulation of prostaglandin E2 synthesis in rabbit synoviocytes. Arthritis Rheumatism 30: 266–273

    Article  PubMed  CAS  Google Scholar 

  64. Crofford LJ, Wilder RL, Ristimäki AP, Sano H, Remmers EF, Epps HR, Hla T (1994) Cyclooxygenase-1 and-2 expression in rheumatoid synovial tissues: effects of interleukin-lß, phorbol ester and corticosteroids. J Clin Invest 93: 1095–1101

    Article  PubMed  CAS  Google Scholar 

  65. Angel J, Berenbaum F, Le Denmat C, Nevalainen T, Masliah J, Fournier C (1994) Interleukin-1-induced prostaglandin E2 biosynthesis in human synovial cells involves the activation of cytosolic phospholipase A2 and cyclooxygenase-2. Eur J Biochem 226: 125–131

    Article  PubMed  CAS  Google Scholar 

  66. Knott I, Dieu M, Burton M, Houblon A, Remade J, Raes M (1994) Induction of cyclooxygenase by interleukin 1: comparative study between human synovial cells and chondrocytes. J Rheumatol 21: 462–466

    PubMed  CAS  Google Scholar 

  67. Geng Y, Blanco FJ, Cornelisson M, Lotz M (1995) Regulation of cyclooxygenase-2 expression in normal human articular chondrocytes. J Immunol 155: 796–801

    PubMed  CAS  Google Scholar 

  68. Berenbaum F, Jacques C, Thomas G, Corvol MT, Béréziat G, Masliah J (1996) Synergistic effect of interleukin-Iß and tumor necrosis factor a on PGE2 production by articular chondrocytes does not involve PLA2 stimulation. Exp Cell Res 222: 379–384

    Article  PubMed  CAS  Google Scholar 

  69. de Brum-Fernandes AJ, Laporte S, Heroux M, Lora M, Patry C, Ménard HA, Dumais R, Leduc R (1994) Expression of prostaglandin endoperoxide synthase-1 and prostaglandin endoperoxide synthase-2 in human osteoblasts. Biochem Biophys Res Commun 198: 955–960

    Article  PubMed  Google Scholar 

  70. Szczepanski A, Moatter T, Carley WW, Gerritsen ME (1994) Induction of cyclooxygenase II in human synovial microvessel endothelial cells by interleukin-1. Arthritis Rheumatism 37: 495–503

    Article  PubMed  CAS  Google Scholar 

  71. Habbib A, Créminon C, Erobert Y, Grassi J, Pradelles P, Maclouf J (1993) Demonstration of an inducible cyclooxygenase in human endothelial cells using antibodies raised against the carboxyl-terminal region of the cyclooxygenase-2. J Biol Chem 268: 23448–23454

    Google Scholar 

  72. Cao C, Matsumura K, Yamagata K, Watanabe Y (1996) Endothelial cells of the rat brain vasculature express cyclooxygenase-2 mRNA in response to systemic interleukin-1: a possible site of prostaglandin synthesis responsible for fever. Brain Res 733: 263–272

    Article  PubMed  CAS  Google Scholar 

  73. Akarasereenont P, Bakhle YS, Thiemermann C, Vane JR (1995) Cytokine-mediated induction of cyclo-oxygenase-2 by activation of tyrosine kinase in bovine endothelial cells stimulated by bacterial lipopolysaccharide. Brit J Pharmacol 115: 401–408

    Article  CAS  Google Scholar 

  74. Blanco A, Habib A, Levy-Toledano S, Maclouf J (1995) Involvement of tyrosine kinases in the induction of cyclo-oxygenase-2 in human endothelial cells. Biochem J 312: 419–423

    PubMed  CAS  Google Scholar 

  75. Jackson BA, Goldstein RH, Roy R, Cozzani M, Taylor L, Polgar P (1993) Effects of Transforming Grovth Factor ß and Interleukin-1ß on expression of cyclooxygenase 1 and 2 and phospholipase A2 mRNA in lung fibroblasts and endothelial cells in culture. Biochem Biophys Res Commun 197: 1465–1474

    Article  PubMed  CAS  Google Scholar 

  76. Yucel-Lindberg T, Ahola H, Nilsson S, Carlstedt-Duke J, Modéer T (1995) Interleukin-1ß induces expression of cyclooxygenase-2 mRNA in human gingival fibroblasts. Inflammation 19: 549–558

    Article  PubMed  CAS  Google Scholar 

  77. Noguchi K, Shitashige M, Yanai M, Morita I, Nishihara T, Murota S, Ishikava I (1996) Prostaglandin production via induction of cyclooxygenase-2 by human gingival fibroblasts stimulated with lipopolysaccharides. Inflammation 20: 5S5–568

    Article  Google Scholar 

  78. Pritchard KA, O’Banion MK, Miano JM, Vlasik N, Bhatia UG, Young DA, Stemerman MB (1994) Induction of cyclooxygenase-2 in rat vascular smooth muscle cells in vitro and in vivo. J Biol Chem 269: 8504–8509

    PubMed  CAS  Google Scholar 

  79. Rimarachin JA, Jacobson JA, Szabo P, Maclouf J, Créminon C, Weksler BB (1994) Regulation of cyclooxygenase-2 expression in aortic smooth muscle cells. Arterioscler Thromb 14: 1021–1031

    Article  PubMed  CAS  Google Scholar 

  80. Mitchell JA, Belvisi MG, Akarasereenont P, Robbins RA, Kwon OJ, Croxtall J, Barnes PJ, Vane JR (1994) Induction of cyclo-oxygenase-2 by cytokines in human pulmonary epithelial cells: regulation by dexamethasone. Br J Pharmacol 113: 1008–1014

    Article  PubMed  CAS  Google Scholar 

  81. Akarasereenont P, Thiemermann C (1996) The induction of cyclo-oxygenase-2 in human pulmonary epithelial cell culture (A549) activated by IL-1ß is inhibited by tyrosine kinase inhibitors. Biochem Biophys Res Commun 220: 181–185

    Article  PubMed  CAS  Google Scholar 

  82. Vadas P, Stefanski E, Wloch M, Grouix B, Van den Bosch H, Kennedy B (1996) Secretory non-pancreatic phospholipase A2 and cyclooxygenase-2 expression by tracheobronchial smooth muscle cells. Eur J Biochem 235: 557–563

    Article  PubMed  CAS  Google Scholar 

  83. Belvisi M, Saunders MA, Haddad EB, Hirst S, Yacoub MH, Barnes PJ, Mitchell JA (1997) Induction of cyclo-oxygenase-2 by cytokines in human cultured airway smooth muscle cells: novel inflammatory role of this cell type. Br J Pharmacol 120: 910–916

    Article  PubMed  CAS  Google Scholar 

  84. Mertz PM, DeWitt DL, Stetler-Stevenson WG, Wahl LM (1994) Interleukin 10 suppression of monocyte prostaglandin H synthase-2. J Biol Chem 269: 21322–21329

    PubMed  CAS  Google Scholar 

  85. Niro H, Otsuka T, Tanabe T, Hara S, Kuga S, Nemoto Y, Tanaka Y, Nakashima H, Kita-jima S, Abe M et al (1995) Inhibition by interleukin-10 of inducible cyclooxygenase expression in lipopolysaccharide-stimulated monocytes: its underlying mechanism in comparison with interleukin-4. Blood 85: 3736–3745

    Google Scholar 

  86. Endo T, Ogushi F, Sone S (1996) LPS-dependent cyclooxygenase-2 induction in human monocytes is down-regulated by IL-13, but not IFN-β. J Immunol 156: 2240–2246

    PubMed  CAS  Google Scholar 

  87. Porreca E, Reale M, Di Febbo C, Di Gioacchino M, Barbacane RC, Castellani ML, Bac-cante G, Conti P, Cuccurullo F (1996) Down-regulation of cyclooxygenase-2 (COX-2) by interleukin-1 receptor antagonist in human monocytes. Immunology 89: 424–429

    Article  PubMed  CAS  Google Scholar 

  88. Onoe Y, Miyaura C, Kaminakayashiki T, Nagai Y, Noguchi K, Qing-Rong C, Seo H, Ohta H, Nozawa S, Kudo I et al. (1996) IL-13 and IL-4 inhibit bone resorption by suppressing cyclooxygenase-2-dependent prostaglandin synthesis in osteoblasts. J Immunol 156: 758–764

    PubMed  CAS  Google Scholar 

  89. Mehindate K, Al-Daccak R, Aoudjit F, Damdoumi F, Fortier M, Borgeat P, Mourad W (1996) Interleukin-4, transforming growth factor ß1, and dexamethasone inhibit super-antigen-induced prostaglandin E2-dependent collagenase gene expression through their action on cyclooxygenase-2 and cytosolic phospholipase A2. Lab Invest 75: 529–538

    PubMed  CAS  Google Scholar 

  90. Newman SP, Flower RJ, Croxtall JD (1994) Dexamethasone suppression of IL-1ß-induced cyclooxygenase 2 expression is not mediated by lipocortin-1 in A549 cells. Biochem Biophys Res Commun 202: 931–939

    Article  PubMed  CAS  Google Scholar 

  91. Ristimäki A, Narko K, Hla T (1996) Down-regulation of cytokine-induced cyclo-oxygenase-2 transcript isoforms by dexamethasone: evidence for post-transcriptional regulation. Biochem J 318: 325–331

    PubMed  Google Scholar 

  92. Wu ce, Croxtall JD, Peretti M, Bryant CE, Thiemermann C, Flower RJ, Vane JR (1995) Lipocortin 1 mediates the inhibition by dexamethasone of the induction by endotoxin of nitric oxide synthase in the rat. Proc Natl Acad Sci USA 92: 3473–3477

    Article  PubMed  CAS  Google Scholar 

  93. Croxtall JD, Newman SP, Choudhury Q, Flower RJ (1996) The concerted regulation of cPLA2, COX2, and lipocortin 1 expression by IL-1ß in A549 cells. Biochem Biophys Res Commun 220: 491–495

    Article  CAS  Google Scholar 

  94. Masferrer JL, Reddy ST, Zweifel BS, Seibert K, Needleman P, Gilbert RS, Herschman HR (1994) In vivo glucocorticoids regulate cyclooxygenase-2 but not cyclooxygenase-1 in peritoneal macrophages. J Pharmacol Exp Ther 270: 1340–1344

    PubMed  CAS  Google Scholar 

  95. Seibert K, Zhang Y, Leahy K, Hauser S; Masferrer J, Perkins W, Lee L, Isakson P (1994) Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA 91: 12013–12017

    Article  PubMed  CAS  Google Scholar 

  96. Masferrer JL, Zweifel BS, Manning PT, Hauser SD, Leahy KM, Smith WG, Isakson PC, Seibert K (1994) Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci USA 91: 3228–3232

    Article  PubMed  CAS  Google Scholar 

  97. Niki H, Tominaga Y, Watanabe-Kobayashi M, Mue S, Ohuchi K (1997) Possible participation of cyclooxygenase-2 in the recurrence of allergie inflammation in rats. Eur J Pharmacol 320: 193–200

    Article  PubMed  CAS  Google Scholar 

  98. Vane JR, Mitchell JA, Appleton I, Tomlinson A, Bishop-Bailey D, Croxtall J, Willough-by DA (1994) Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation. Proc Natl Acad Sci USA 91: 2046–2050

    Article  PubMed  CAS  Google Scholar 

  99. Appleton I, Tomlinson A, Mitchell JA, Willoughby DA (1995) Distribution of cyclooxygenase isoforms in murine chronic granulomatous inflammation. Implications for future anti-inflammatory therapy. J Pathol 176: 413–420

    Article  PubMed  CAS  Google Scholar 

  100. Sano H, Hla T, Maier JAM, Crofford LJ, Case JP, Naciag T, Wilder RL (1992) In vivo cyclooxygenase expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis. J Clin Invest 89: 97–108

    Article  PubMed  CAS  Google Scholar 

  101. Anderson CD, Hauser SD, McGarity KL, Bremer ME, Isakson PC, Gregory SA (1996) Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. J Clin Invest 97: 2672–2679

    Article  PubMed  CAS  Google Scholar 

  102. Tomlinson A, Appleton I, Moore AR, Gilroy DW, Willis D, Mitchell JA, Willoughby DA (1994) Cyclo-oxygenase and nitric oxide synthase isoforms in rat carrageenin-induced pleurisy. Br J Pharmacol 113: 693–698

    Article  PubMed  CAS  Google Scholar 

  103. Pairet M, Engelhardt G (1996) Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: possible physiological and therapeutic implications. Fund Clin Pharmacol 10: 1–15

    Article  CAS  Google Scholar 

  104. Dinchuk JE, Car BD, Focht RJ, Johnston JJ, Jaffee BD, Covington MB, Contel NR, Eng VM, Collins RJ, Czerniak PM et al. (1995) Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II Nature 378: 406–409

    Article  PubMed  CAS  Google Scholar 

  105. Morham SG, Langenbach R, Loftin CD, Tiano HF, Vouloumanos N, Jennette JC, Mahler JF, Kluckman KD, Ledford A, Lee CA et al (1995) Prostaglandin synthase gene disruption causes severe renal pathology in the mouse. Cell 83: 473–482

    Article  PubMed  CAS  Google Scholar 

  106. DeWitt D, Smith WL (1995) Yes, but do they still get headaches. Cell 83: 345–348

    Article  PubMed  CAS  Google Scholar 

  107. Crofford LJ. (1996) Expression and regulation of cyclooxygenase-2 in synovial tissues of arthritic patients. In: N Bazan J Botting J Vane (eds): New targets in inflammation: inhibitors of COX-2 or adhesion molecules. Kluwer Academic Publishers Dordrecht 83–9

    Google Scholar 

  108. Carreira PE, Iniquez MA, Pablos JL, Cabré F, Gomez-Reino JJ (1996) Detection of COX-1 and COX-2 isoforms in synovial fluid from patients vith inflammatory joint diseases. Arthritis Rheumatism 39 (Suppl 9): Abstract 327

    Google Scholar 

  109. Carreira PE, Iniquez MA, Pablos JL, Cabré F, Gomez-Reino JJ (1996) Detection of COX-1 and COX-2 isoforms in synovial fluid from patients vith inflammatory joint diseases. Arthritis Rheumatism 39 (Suppl 9): Abstract 327

    Google Scholar 

  110. van Ryn J, Pairet M (1997) Selective cyclooxygenase-2 inhibitors: pharmacology, clinical effects and therapeutic potential. Exp Opin Invest Drugs 6: 609–614

    Article  Google Scholar 

  111. Pairet M, van Ryn J, Mauz A, Schierok H, Diederen W, Türck D, Engelhardt G (1998) Differential inhibition of COX-1 and COX-2 by NSAIDs: a summary of results obtained using various test systems. In: J Vane, J Botting (eds): Selective cyclooxygenase-2 inhibitors: pharmacology, clinical effects and therapeutic potential. Kluwer Academic Publishers, Dordrecht, 27–46

    Google Scholar 

  112. Engelhardt G, Homma D, Schlegel K, Utzmann R, Schnitzlet C (1995) Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-stroidal anti-inflammatory agent with favourable gastrointestinal tolerance. Inflamm Res 44: 423–433

    Article  PubMed  CAS  Google Scholar 

  113. Engelhardt G, Homma D, Schnitzlet C (1995) Meloxicam: a potent inhibitor of adjuvant arthritis in the lewis rat. Inflamm Res 44: 548–555

    Article  PubMed  CAS  Google Scholar 

  114. Engelhardt G, Bögel R, Schnitzlet C, Utzmann R (1996) Meloxicam: influence on arachidonic acid metabolism. Part 2. In vivo findings. Biochem Pharmacol 51: 29–38

    Article  PubMed  CAS  Google Scholar 

  115. Pairet M, Churchill L, Trummlitz G, Engelhardt G (1996) Differential inhibition of cyclooxygenase-1 (COX-1) and-2 (COX-2) by NSAIDs: consequences on anti-inflammatory activity versus gastric and renal safety. Inflammopharmacology 4: 61–70

    Article  CAS  Google Scholar 

  116. Pairet M, Churchill L, Engelhardt G. (1996) Differential inhibition of cyclooxygenases 1 and 2 by NSAIDs. In: N Bazan, J Botting, J Vane (eds): New targets in inflammation: inhibitors of COX-2 and adhesion molecules. Kluwer Academic Publishers, Dordrecht, 23–38

    Google Scholar 

  117. Churchill L, Graham A, Shih CK, Pauletti D, Farina PR, Grob PM (1996) Selective inhibition of human cyclo-oxygenase-2 by meloxicam. Inflammopharmacology 4: 125–135

    Article  CAS  Google Scholar 

  118. Engelhardt G, Bögel R, Schnitzlet C, Utzmann R (1996). Meloxicam: influence on arachidonic acid metabolism. Part 1. In vitro findings. Biochem Pharmacol 51: 21–28

    Article  PubMed  CAS  Google Scholar 

  119. Patrignani P, Panara MR, Santini G, Sciulli MG, Padovano R, Cipollone F, Patrono C (1996) Differential inhibition of cyclooxygenase activity and prostaglandin endoperox-ide synthase isozymes in vitro and ex vivo in man. Prostaglandins Leukotrienes and Essential Fatty Acids 55 (Suppl 1): Abstract P115

    Article  Google Scholar 

  120. Riendeau D, Percival MD, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Falgueyret JP, Ford-Hutchinson AW et al (1997) Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Br J Pharmacol 121: 105–117

    Article  PubMed  CAS  Google Scholar 

  121. Swingle KF, Moore GGI (1984) PrecHnical pharmacological studies with nimesulide. Drugs Exp Clin Res 10: 587–597

    CAS  Google Scholar 

  122. Carr DP, Henn R, Green JR, Böttcher I (1986) Comparison of the systemic inhibition of thromboxane synthesis, anti-inflammatory activity and gastro-intestinal toxicity of nonsteroidal anti-inflammatory drugs in the rat. Agents Actions 19: 374–375

    Article  PubMed  CAS  Google Scholar 

  123. Velo GP (1991) The anti-inflammatory, analgesic and antipyretic activity of nimesulide in experimental methods. Drug Invest 3 (Suppl 2): 10–13

    Article  Google Scholar 

  124. Huff R, Collins P, Kramer S, Seibert K, Koboldt C, Gregory S, Isakson P (1995) A structural feature of N-[2-8cyclohexyloxy)-4-nitrophenyl] methanesulfonamide (NS-398) that governs their selectivity and affinity for cyclooxygenase 2 (COX2). Inflamm Res 44 (Suppl 2): S145–S146

    Article  PubMed  CAS  Google Scholar 

  125. Prasit P, Black WC, Chan CC, Ford-Hutchinson AW, Gauthier JY, Gordon R, Guay D, Kargman S, Lau CK, Li CS et al (1995) L-745, 337: a selective cyclooxygenase-2 inhibitor. Med Chem Res 5: 364–374

    CAS  Google Scholar 

  126. Taniguchi Y, Ikesue A, Yokoyama K, Noda K, Debuchi H, Nakamura T, Toda A, Shi-meno H (1995) Selective inhibition by nimesulide, a novel non-steroidal anti-inflammatory drug, with prostaglandin endoperoxide synthase-2 activity in vitro. Pharmaceut Sci 1: 173–175

    Google Scholar 

  127. Tavares IA, Bishai PM, Bennett A (1995) Activity of nimesulide on constitutive and inducible cyclooxygenases. Arzneim Forsch/Drug Res 45: 1093–1095

    CAS  Google Scholar 

  128. Young JM, Panah S, Satchawatcharaphong C, Cheung PS (1996) Human whole blood assays for inhibition of prostaglandin G/H synthases-1 and-2 using A23187 and lipopolysaccharide stimulation of thromboxane B2 production. Inflamm Res 45: 246–253

    Article  PubMed  CAS  Google Scholar 

  129. Miralpex M, Camacho M, Lopez-Belmonte J, Canalias F, Beleta J, Palacios JM, Vila L (1997) Selective induction of cyclo-oxygenase-2 activity in the permanent human endothelial cell line HUV-EC-C: biochemical and pharmacological chracterization. Br J Pharmacol 121: 171–180

    Article  Google Scholar 

  130. Martel RR, Klicius J (1982) Comparison in rats of the anti-inflammatory and gastric irritant effects of etodolac with several clinically effective anti-inflammatory drugs. Agents Actions 12: 295–297

    Article  PubMed  CAS  Google Scholar 

  131. Glaser K, Sung ML, O’Neill K, Belfast M, Hartman D, Carlson R, Kreft A, Kubrak D, Hsiao CL, Weichman B (1995) Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1. Eur J Pharmacol 281: 107–111

    Article  PubMed  CAS  Google Scholar 

  132. Wong E, DeLuca C, Boily C, Charleson S, Cromlish W, Denis D, Kargman S, Kennedy BP, Ouellet M, Skorey K et al (1997) Characterization of autocrine inducible prostaglandin H synthase-1 (PGHS-2) in human osteosarcoma cells. Inflamm Res 46: 51–59

    Article  PubMed  CAS  Google Scholar 

  133. Wiesenberg-Boettcher I, Schweizer A, Green JR, Mueller K, Maerki F, Pfeilschifter J (1989) The pharmacological profile of CGP 28238, a novel highly potent anti-inflammatory compound. Drugs Exp Clin Res 15: 501–509

    PubMed  CAS  Google Scholar 

  134. Klein T, Niising R, Pfeilschifter J, Ulrich V (1994) Selective inhibition of cyclooxygenase 2. Biochem Pharmacol 48: 1605–1610

    Article  PubMed  CAS  Google Scholar 

  135. Brideau C, Kargman S, Liu S, Dallob AL, Ehrich EW, Rodger IW, Chan CC (1996) A human whole blood assay for clinical evaluation of biochemical efficacy of cylooxyge-nase inhibitors. Inflamm Res 45: 68–74

    Article  PubMed  CAS  Google Scholar 

  136. Cromlish L, Kennedy BP (1996) Selective inhibition of cyclooxygenase-1 and-2 using intact insect cell assays. Biochem Pharmacol 52: 1777–1785

    Article  PubMed  CAS  Google Scholar 

  137. Gans KR, Gabraight W, Roman RJ, Haber SB, Kerr JS, Schnidt WK, Smith C, Hewes WE, Ackerman NR (1990) Anti-inflammatory and safety profile of DuP 697, a novel orally effective prostaglandin synthesis inhibitor. J Pharmacol Exp Ther 254: 180–187

    PubMed  CAS  Google Scholar 

  138. Copeland RA, Williams JM, Giannaras J, Nürnberg S, Covington M, Pinto D, Pick S, Trzaskos J (1994) Mechanism of selective inhibition of the inducible form of prostaglandin G/H synthase. Proc Natl Acad Sci USA 91: 11202–11206

    Article  PubMed  CAS  Google Scholar 

  139. Gierse JK, Häuser SD, Creely DP, Koboldt C, Rangwala SH, Isakson PC, Seibert K (1995) Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase. Biochem J 305: 479–484

    PubMed  CAS  Google Scholar 

  140. Kargman S, Wong E, Greig GM, Falgueyret JP, Cromlish W, Eithier D, Yergey JA, Rien-deau D, Evans JF, Kennedy B et al (1996) Mechanism of selective inhibition of human prostaglandin G/H synthase-1 and-2 in intact cells. Biochem Pharmacol 52: 1113–1125

    Article  PubMed  CAS  Google Scholar 

  141. Futaki N, Arai I, Hamasaka Y, Takahashi S, Higuchi S, Otomo S (1993) Selective inhibition of NS-398 on prostanoid production in inflamed tissue in rat carrageenan-air-pouch inflammation. J Pharm Pharmacol 45: 753–755

    Article  PubMed  CAS  Google Scholar 

  142. Futaki N, Yoshikava K, Hamasaka Y, Arai I, Higuchi S, Izuka H, Otomo S (1993) NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions. Gen Pharmac 24: 105–110

    Article  CAS  Google Scholar 

  143. Barnett J, Chow J, Ives D, Chiou M, Mackenzie R, Osen E, Nguyen B, Tsing S, Bach C, Freire J et al. (1994) Purification, characterization and selective inhibition of human prostaglandin G/H synthase 1 and 2 expressed in the baculovirus system. Biochim Bio-phys Acta 1209: 130–139

    Article  CAS  Google Scholar 

  144. Futaki N, Takahashi S, Yokoyama M, Arai I, Higuchi S, Otomo S (1994) NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/ cyclooxygenase (COX-2) activity in vitro. Prostaglandins 47: 55–59

    CAS  Google Scholar 

  145. Reitz DB, Li JL, Norton MB, Reinhard EJ, Collins JT, Anderson GD, Greggory SA, Koboldt CM, Perkins WE, Seibert K et al (1994) Selective cyclooxygenase inhibitors: novel 1, 2-diarylcyclopentenes are potent and orally active COX-2 inhibitors. J Med Chem 37: 3878–3881

    Article  PubMed  CAS  Google Scholar 

  146. Pairet M, Schmidberger C, Engelhardt G (1996) Effect of meloxicam and SC 58125 on adjuvant arthritis in the rat. Rheumatology in Europe 25 (Suppl 1): Abstract 445

    Google Scholar 

  147. Panara MR, Greco A, Santini G, SciulU MG, Rotondo MT, Padovano R, di Giamber-ardino M, Cipollone F, Cuccurullo F, Patrono C et al (1995) Effects of the novel anti-inflammatory compounds, N-[2-(cyclohexyloxy)-4-nitrophenyl] methanesulphonamide (NS-398) and 5-methanesulphonamido-6-(2, 4-difluorothiophenyl)-1-indanone (L-745, 337) on the cyclo-oxygenase activity of human blood prostaglandin endoperoxide synthases. Br J Pharmacol 116: 2429–2434

    Article  PubMed  CAS  Google Scholar 

  148. Chan CC, Boyce S, Brideau C, Ford-Hutchinson AW, Gordon R, Guay D, Hill RG, Li CS, Mancini J, Penneton M et al (1995) Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745, 337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. J Pharmacol Exp Ther 274: 1531–1537

    PubMed  CAS  Google Scholar 

  149. Visco D, Widmer R, Shen F, Orevillo C, Christen A, Chung C, Leger S, Prasit P, Therien M, Wang Z et.al (1996) The effects of a selective cyclooxygenase-2 (COX-2) inhibitor on adjuvant-induced arthritis in the rat. Prostaglandins Leukotrienes and Essential Fatty Acids 55 (Suppl 1): Abstract P202

    Google Scholar 

  150. Pairet M, Schmidberger C, van Ryn J, PĂĽschner H (1997) Effect of indomethacin, meloxicam and L-745, 337 on adjuvant arthritis in the rat. ILAR Congress of Rheumatology, Singapore, 8-13 June, Abstract book p. 158}

    Google Scholar 

  151. Kishimoto Y, Wada K, Nakamoto K, Kitano M, Kamisaki Y, Kawasaki H, Itoh T (1996) Development of the system to estimate expression level of COX-2 message in gastric injury induced by ischemia-reperfusion in rats. Prostaglandins Leukotrienes and Essential Fatty Acids 55 (Suppl 1): Abstract P203

    Google Scholar 

  152. Peskar BM, Stroff T, Halter F, Schmassmann A (1996) Effect of L-745, 337, a selective inhibitor of cyclooxygenase 2, on healing of chronic gastric ulcers in rats. Prostaglandins Leukotrienes and Essential Fatty Acids 55 (Suppl 1): Abstract 147

    Google Scholar 

  153. Reuter BK, Asfaha S, Buret A, Sharkey KA, Wallace JL (1996) Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygnase-2. J Clin Invest 98: 2076–2085

    Article  PubMed  CAS  Google Scholar 

  154. Parnham M (1997) Selective COX-2 inhibitors. DN&P 10: 182–187

    Google Scholar 

  155. Stichtenoth DO, Wagner B, Frölich JC (1997) Effects of meloxicam and indomethacin on cyclooxygenase pathways in healthy volunteers. J Invest Med 45: 44–49

    CAS  Google Scholar 

  156. Frölich JC, Stichtenoth DO (1998) Renal side effects of NSAIDs: role of COX-1 and COX-2. In: J Vane, J Botting (eds): Selective cyclooxygenase-2 inhibitors: pharmacology, clinical effects and therapeutic potential. Kluwer Academic Publishers Dordrecht, 87–98

    Google Scholar 

  157. Lemmel EM, Bolten W, Burgos-Vargas R, Piatt P, Nissilä M, Sahlberg D, Björneboe O, Baumgartner H, Valat JP, Franchimont P et al (1997) Efficacy and safety of meloxicam in patients with rheumatoid arthritis. J Rheumatol 24: 282–90

    PubMed  CAS  Google Scholar 

  158. Bolten W (1996) Clinical experience with meloxicam, a selective COX-2 inhibitor. In: N Bazan, J Botting, J Vane (eds): New targets in inflammation: inhibitors of COX-2 and adhesion molecules. Kluwer Academic Publishers Dordrecht 105–116

    Google Scholar 

  159. Lund B, Distel M, Bluhmki E (1994) A double-blind placebo controlled study of three different doses of meloxicam in patients with osteoarthritis of the knee. Scand J Rheumatol Suppl 98, Abstract 117

    Google Scholar 

  160. Goei The H, Lund B, Distel M, Bluhmki E (1995) A double-blind randomised trial comparing meloxicam with diclofenac in osteoarthritis. Rheumatology in Europe 24 (suppl 3): 325, Abstract E51

    Google Scholar 

  161. Hosie J, Distel M, Bluhmki E (1995) A six month, double-blind study comparing meloxicam 15 mg with piroxicam 20 mg in osteoarthritis. Rheumatology in Europe 24 (suppl 3): 325, Abstract E50

    Google Scholar 

  162. Hosie J, Distel M, Bluhmki E (1996) Meloxicam in osteoarthritis: a six-month, double-blind comparison with diclofenac sodium. Br J Rheumatol 35 (Suppl 1): 39–43

    Article  PubMed  CAS  Google Scholar 

  163. Lindén B, Distel M, Bluhmki E (1996) A double-blind study to compare the efficacy and safety of meloxicam 15 mg with piroxicam 20 mg in patients with osteoarthritis of the hip. Br J Rheumatol 35 (Suppl 1): 35–38

    Article  PubMed  Google Scholar 

  164. Distel M, Mueller C, Bluhmki E (1996) Global analysis of gastrointestinal safety of a new NSAID, meloxicam. Inflammopharmacology 4: 71–81

    Article  CAS  Google Scholar 

  165. Patoia L, Santucci L, Furno M, Dionisi MS, Dell’Orso M, Romagnoli M, Satarinia A, Marini MG (1996) A 4-week double-blind parallel-group study to compare the gastrointestinal effects of meloxicam 7.5 mg, meloxicam 15 mg, piroxicam 20 mg and placebo by means of faecal blood loss, endoscopy and symptom evaluation in healthy volunteers. Br J Rheumatol 35 (suppl 1): 61–67

    Article  PubMed  CAS  Google Scholar 

  166. Bevis PJR, Bird HA, Lapham G (1996) An open study to assess the safety and tolerability of meloxicam 15 mg in subjects with rheumatic disease and mild renal impairment. Br J Rheumatol 35 (suppl 1): 56–60

    Article  PubMed  CAS  Google Scholar 

  167. Hawkey C, Kahan A, Steinbrück K, Alegre C, Baumelou E Bégaud B, Dequeker J, Isomäki H, Littlejohn G, Mau J, Papazoglou S, and the international MELISSA Study Group (1998) Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. Brit J Rheumatol; in press

    Google Scholar 

  168. Dequeker J, Hawkey C, Kahan A, Steinbrück K, Alegre C, Baumelou E, Bégaud B, Isomäki H, Littlejohn G, Mau J, Papazoglou S, on behalf of the Select study group (1998) Improvement in gastrointestinal tolerability of the selective COX-2 inhibitor, meloxicam, compared with piroxicam: results of the safety and efficacy large scale evaluation of COX inhibiting therapies (SELECT) trial in osteoarthritis. Brit J Rheumatol; in press

    Google Scholar 

  169. Cullen L, Kelly L, Coyle D, Forde R, Fitzgerald D (1996) Selective suppression of COX-2 during chronic administration of nimesulide in man. William Harvey Research Conference: Selective COX-2 Inhibitors; pharmacology, clinical effects and therapeutic potential, Cannes, 20-21 March, Abstract P3

    Google Scholar 

  170. Steinhäuslin F, Munajo A, Buclin T, Macciochi A, Biollaz J (1993) Renal effects of nimesulide in furosemide-treated subjects. Drugs 46 (Suppl 1): 257–262

    Article  PubMed  Google Scholar 

  171. Davis R, Brogden RN (1994) Nimesulide. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 48: 431–454

    Article  PubMed  CAS  Google Scholar 

  172. Bourgeois P, Dreiser RL, Lequesne MG, Macciocchi A, Monti T (1994) Multi-centre double-blind study to define the most favourable dose of nimesulide in terms of efficacy/safety ratio in the treatment of osteoarthritis. Eur J Rheumatol Inflamm 14: 39–50

    PubMed  CAS  Google Scholar 

  173. Lücker PW, Pawlovwski C, Friedrich I, Faiella F, Magni E (1994) Double-blind, randomised, multi-centre clinical study evaluating the efficacy and tolerability of nimesulide in comparison with etodolac in patients suffering from osteoarthritis of the knee. Eur J Rheumatol Inflamm 14: 29–38

    PubMed  Google Scholar 

  174. Quattrini M, Paladin S (1995) A double-blind study comparing nimesulide with naproxen in the treatment of osteoarthrosis of the hip. Clin Drug Invest 10: 139–146

    Article  CAS  Google Scholar 

  175. Cipollini F, Mecozzi V, Altilia F (1989) Endoscopic assessment of the effects of nimesulide on the gastric mucosa: comparison with indomethacin. Curr Ther Res 45: 1042–1047

    Google Scholar 

  176. Marini U, Spotti D, Magni E, Monti T (1990) Double-blind endoscopic study comparing the effect of nimesulide and placebo on gastric mucosa of dyspeptic subjects. Drug Invest 2: 162–166

    Article  Google Scholar 

  177. Garcia Rodriguez LA, Cattaruzzi C, Troncon MG, Agostinis L (1998) Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. Arch Intern Med 158: 33–39

    Article  PubMed  CAS  Google Scholar 

  178. Taha AS, McLaughlin S; Holland PJ, Kelly RW, Sturrock RD, Russell RI (1990) Effect on gastric and duodenal mucosal prostaglandins of repeated intake of naproxen and etodolac in rheumatoid arthritis. Ann Rheum Dis 49: 354–358

    Article  PubMed  CAS  Google Scholar 

  179. Balfour JA, Buckley MMT (1991) Etodolac: A reappraisal of its pharmacology and therapeutic use in rheumatic diseases and pain states. Drugs 42: 274–299

    Article  PubMed  CAS  Google Scholar 

  180. Spencer-Green G (1997) Low dose etodolac in rheumatoid arthritis: a review of early studies. J. Rheumatol 24 (suppl 47): 3–9

    Google Scholar 

  181. Lightfoot R (1997) Comparison of the efficacy and safety of etodolac and piroxicam in patients with rheumatoid arthritis. J Rheumatol 24 (suppl 47): 10–16

    Google Scholar 

  182. Bacon PA (1990) An overview of the efficacy of etodolac in arthritic disorders. Eur J Rheumatol and Inflamm 10: 22–34

    CAS  Google Scholar 

  183. Paulsen GA, Baigun S, de Figueiredo JG, de Freitas GG (1991) Efficacy and tolerability comparison of etodolac and piroxicam in the treatment of patients with osteoarthritis of the knee. Curr Med Res Opin 12: 40–41

    Google Scholar 

  184. Schnitzer TJ, Constantine G (1994): Etodolac in the treatment of osteoarthritis, recent studies. J Rheumatol 24 (suppl 47): 23–31

    Google Scholar 

  185. Lanza F, Rack MF, Lynn M, Wolf J, Sanda M (1987) An endoscopic comparison of the effects of etodolac, indomethacin, ibuprofen, naproxen, and placebo on the gastrointestinal mucosa. J Rheumatol 14: 338–341

    PubMed  CAS  Google Scholar 

  186. Lanza F, Panagides J, Salom IL (1986) Etodolac compared with aspirin: an endoscopic study of gastrointestinal tracts of normal volunteers. J Rheumatol 13: 299–303

    PubMed  CAS  Google Scholar 

  187. Van Eeden A, Schotborgh RH, Tygat GNJ (1990) An endoscopic evaluation of the effects of etodolac and diclofenac on the gastric and duodenal mucosa. Clin Ther 12: 496–502

    PubMed  Google Scholar 

  188. Russell RI (1990) Endoscopic evaluation of etodolac and naproxen and their relative eff-fects on gastric and duodenal prostaglandins. Rheumatol Int 10: 17–21

    Article  PubMed  Google Scholar 

  189. Neustadt DH (1997) Double-blind evaluation of the longterm effects of etodolac versus ibuprofen in patients with rheumatoid arthritis. J Rheumatol 24 (suppl 47): 17–22

    Google Scholar 

  190. Bjarnason I, Macpherson A, Rotman H, Schupp J, Hayllar J (1997) A randomized, double-blind, crossover comparative endoscopy study on the gastroduodenal tolerability of a highly specific cyclooxygenase-2 inhibitor, flosulide, and naproxen. Scand J Gastroenterol 32: 126–130

    Article  PubMed  CAS  Google Scholar 

  191. Brunei P, Hornych A, Guyene TT, Sioufi A, Turri M, Menard J (1995) Renal and endocrine effects of flosulide, after single and repeated administration to healthy volunteers. Eur J Clin Pharmacol 49: 193–201

    Google Scholar 

  192. Penning TD, Talley JJ, Berteshaw SR, Carter JS, Collins PW, Docter SD, Graneto MJ, Lee LP, Malecha JW, Miyashiro JM et al. (1997) Synthesis and biological evaluation of the 1, 5-diarylpyrazol class of cyclooxygenase-2 inhibitors: Identification of 4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58735, celecoxib). J Med Chem 40: 1347–1365

    Article  PubMed  CAS  Google Scholar 

  193. Schwartz B, Hurley SM, Hubbard RC Yu SS, Talwalker S, Isakson P, Geis GS (1997) A pilot study of the platelet effects of SC-58635, a novel COX-2 selective inhibitor. ILAR Congress of Rheumatology, Singapore, 8-13 June, Abstract Book p. 159

    Google Scholar 

  194. Lipsky PE (1997) COX-2 inhibition in patients with arthritis: Theory and practice. APLAR Journal of Rheumatology 1: 69–72

    Google Scholar 

  195. Lipsky PE (1997) Selective COX-2 inhibition in arthritis. ILAR Congress of Rheumatology, Singapore, 8-13 June

    Google Scholar 

  196. Isakson P, Zweifel B, Masferrer J, Koboldt C, Seibert K, Hubbard R, Geis S, Needleman P (1998) Specific COX-2 inhibitors: from bench to bedside. In: J. Vane, J Botting (eds): Selective cyclooxygenase-2 inhibitors: pharmacology, clinical effects and therapeutic potential. Kluwer Academic Publishers Dordrecht, 127–133

    Google Scholar 

  197. Hubbard RC, Koepp R, Yu SS, Talwalker S, Geis GS, Weisenhutter CW, Makarowshi WS (1997) A pilot study of the efficacy of SC-58635, a novel COX-2 selective inhibitor, in treating osteoarthritis. ILAR Congress of Rheumatology, Singapore, 8-13 June, Abstract Book p. 46

    Google Scholar 

  198. Ford-Hutchinson AT (1998) New highly selective COX-2 inhibitors. In: J Vane, J Botting (eds): Selective cyclooxygenase-2 inhibitors: pharmacology, clinical effects and therapeutic potential. Kluwer Academic Publishers, Dordrecht, 117–125

    Google Scholar 

  199. Ehrich E, Dallob A, Van Hacken A, Depré M, DeLepeleire I, DeSchepper C, Gertz B (1996) Demonstration of selective COX-2 inhibition by MK-966 in humans. Arthritis and Rheumatism 39 (Suppl 9): Abstract 328

    Google Scholar 

  200. Ehrich E, Mehlisch D, Perkins S, Brown P, Wittreich J, Lipschutz K, Gertz B (1996) Efficacy of MK-966, a highly selective inhibitor of COX-2 in the treatment of postoperative dental pain. Arthritis and Rheumatism 39 (Suppl 9): Abstract 329

    Google Scholar 

  201. Ehrich E, Schnitzer T, Mcilwain H, Levy R, Wolfe F, Weisman W, Morrison B, Bolog-nese J (1997) MK-966, a highly selective COX-2 inhibitor, is effective in the treatment of osteoarthritis in a 6-week pilot study. ILAR Congress of Rheumatology, Singapore, 8-13 June, Abstract Book p. 47

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biological Research and Department of Medicine, Boehringer Ingelheim, Birkendorfer Str. 65, D-88397, Biberach/Riss, Germany

    Michel Pairet

  2. Department of Biological Research and Department of Medicine, Boehringer Ingelheim, Birkendorfer Str. 65, D-88397, Biberach/Riss, Germany

    Joanne van Ryn & Manuel Distel

Authors
  1. Michel Pairet
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joanne van Ryn
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Manuel Distel
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Experimental Pathology, St. Bartholomew’s and The Royal London School of Medicine and Dentistry, Charterhouse Square, London, EC1M 6BQ, UK

    Derek A. Willoughby  & Annette Tomlinson  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer Basel AG

About this chapter

Cite this chapter

Pairet, M., van Ryn, J., Distel, M. (1999). Overview of COX-2 in inflammation: from the biology to the clinic. In: Willoughby, D.A., Tomlinson, A. (eds) Inducible Enzymes in the Inflammatory Response. Progress in Inflammation Research. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-8747-2_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-0348-8747-2_1

  • Publisher Name: Birkhäuser, Basel

  • Print ISBN: 978-3-0348-9755-6

  • Online ISBN: 978-3-0348-8747-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation